肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：Sipuleucel-T诱导的抗原特异性CD8亚型与患者总生存有关

2018-10-22 MedSci MedSci原创

Sipuleucel-TCD8总生存
关注

IMPACT试验结果表明，接受sipuleucel-T治疗的患者与对照患者相比中位总生存期（OS）延长为4.1个月。因此Sipuleucel-T被FDA批准用于治疗转移性去势抵抗性前列腺癌（mCRPC）。尽管sipuleucel-T的有效性已经得到证明，但其机制仍未完全阐明。CLIN CANCER RES近期发表了一篇文章，研究这一问题。

IMPACT试验结果表明，接受sipuleucel-T治疗的患者与对照患者相比中位总生存期（OS）延长为4.1个月。因此Sipuleucel-T被FDA批准用于治疗转移性去势抵抗性前列腺癌（mCRPC）。尽管sipuleucel-T的有效性已经得到证明，但其机制仍未完全阐明。CLIN CANCER RES近期发表了一篇文章，研究这一问题。

作者评估了三个sipuleucel-T试验的患者样本对免疫原PA2024和靶标抗原前列腺酸性磷酸酶（PAP）的外周细胞学免疫应答。为了评估细胞毒性T淋巴细胞（CTL）活性，作者检测了接受sipuleucel-T治疗的患者和健康志愿者样品中PAP-或PA2024-特异性CD8+T细胞的表面CD107a的表达。研究结果表明，在sipuleucel-T治疗后观察到PA2024特异性CD4+（P = 0.030）和CD8+（P = 0.052）T细胞增殖增加，与PAP相比出现更强的PA2024特异性反应。在sipuleucel-T治疗后的第6周和第26周，PAP-和PA2024-CTL活性（CD107a阳性）显着增加。在sipuleucel-T治疗后26周，OS与PA2024 CTL活性有关。治疗26周PA2024-CTL活性升高OS改善有关，而PA2024反应与26周PAP反应有关。

文章最后认为，该研究首次报道了由sipuleucel-T治疗引起的PAP特异性CD8+T细胞反应。PA2024特异性CTL活性的增加与PAP特异性CTL活性增加以及OS改善相关。

原始出处：

Emmanuel S. Antonarakis, Eric J. et al. Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival. CLIN CANCER RES. October 2018 doi: 10.1158/1078-0432.CCR-18-0638

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

 

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1899246, encodeId=41ff1899246f9, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sun Apr 07 23:43:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605388, encodeId=40511605388ad, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Wed Oct 24 06:43:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623313, encodeId=1f261623313e2, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Wed Oct 24 06:43:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961219, encodeId=c65b1961219d0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Mar 01 17:43:00 CST 2019, time=2019-03-01, status=1, ipAttribution=)]
    2019-04-07 jinweidong

    #特异性#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1899246, encodeId=41ff1899246f9, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sun Apr 07 23:43:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605388, encodeId=40511605388ad, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Wed Oct 24 06:43:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623313, encodeId=1f261623313e2, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Wed Oct 24 06:43:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961219, encodeId=c65b1961219d0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Mar 01 17:43:00 CST 2019, time=2019-03-01, status=1, ipAttribution=)]
    2018-10-24 ms691033630344116

    #CD8#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1899246, encodeId=41ff1899246f9, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sun Apr 07 23:43:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605388, encodeId=40511605388ad, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Wed Oct 24 06:43:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623313, encodeId=1f261623313e2, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Wed Oct 24 06:43:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961219, encodeId=c65b1961219d0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Mar 01 17:43:00 CST 2019, time=2019-03-01, status=1, ipAttribution=)]
    2018-10-24 xiaoyeshuang

    #抗原#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1899246, encodeId=41ff1899246f9, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sun Apr 07 23:43:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605388, encodeId=40511605388ad, content=<a href='/topic/show?id=94c9436340' target=_blank style='color:#2F92EE;'>#CD8#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4363, encryptionId=94c9436340, topicName=CD8)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4bac19388006, createdName=ms691033630344116, createdTime=Wed Oct 24 06:43:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623313, encodeId=1f261623313e2, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Wed Oct 24 06:43:00 CST 2018, time=2018-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1961219, encodeId=c65b1961219d0, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Mar 01 17:43:00 CST 2019, time=2019-03-01, status=1, ipAttribution=)]
    2019-03-01 维他命

    #CEL#

    0

相关资讯

肿瘤免疫治疗时代已经到来？

       离最早研究者提出可以训练机体免疫系统自己杀伤肿瘤的理论，已经过去100 多年，该领域顶级专家认为，这一理论会在明后年最终证实自己。       美国Dana-Farber 癌症中心Glenn Dranoff 教授指出，“我们已经进入了一个新的时期，免疫治疗将成为抗肿